TW200520800A - Hyaluronic acid compound, hydrogel thereof and material for treating joint - Google Patents
Hyaluronic acid compound, hydrogel thereof and material for treating joint Download PDFInfo
- Publication number
- TW200520800A TW200520800A TW093132785A TW93132785A TW200520800A TW 200520800 A TW200520800 A TW 200520800A TW 093132785 A TW093132785 A TW 093132785A TW 93132785 A TW93132785 A TW 93132785A TW 200520800 A TW200520800 A TW 200520800A
- Authority
- TW
- Taiwan
- Prior art keywords
- hyaluronic acid
- acid compound
- patent application
- ethanolamine
- phospholipids
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 55
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 54
- -1 Hyaluronic acid compound Chemical class 0.000 title claims abstract description 35
- 239000000463 material Substances 0.000 title claims description 13
- 239000000017 hydrogel Substances 0.000 title abstract description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 26
- 210000000845 cartilage Anatomy 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000000416 hydrocolloid Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 210000000629 knee joint Anatomy 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract description 3
- 230000002980 postoperative effect Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000031737 Tissue Adhesions Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 45
- 150000003904 phospholipids Chemical class 0.000 description 31
- 230000000052 comparative effect Effects 0.000 description 12
- 230000007547 defect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 229920002385 Sodium hyaluronate Polymers 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 150000002169 ethanolamines Chemical class 0.000 description 10
- 229940010747 sodium hyaluronate Drugs 0.000 description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000012736 aqueous medium Substances 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 108010045569 atelocollagen Proteins 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- 235000015655 Crocus sativus Nutrition 0.000 description 2
- 244000124209 Crocus sativus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000004417 patella Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000013974 saffron Nutrition 0.000 description 2
- 239000004248 saffron Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- OQQOAWVKVDAJOI-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-UHFFFAOYSA-N 0.000 description 1
- CPTRNWZHRHBEGH-JEDNCBNOSA-N (2s)-2-amino-4-methylpentanoic acid;chloromethane Chemical compound ClC.CC(C)C[C@H](N)C(O)=O CPTRNWZHRHBEGH-JEDNCBNOSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZSCUXKJGNXUNNH-UHFFFAOYSA-N 2-[4-[2-[[[2-(4-bromothiophen-2-yl)-2-hydroxyethyl]amino]methyl]phenoxy]butyl]isoindole-1,3-dione Chemical compound C=1C=CC=C(OCCCCN2C(C3=CC=CC=C3C2=O)=O)C=1CNCC(O)C1=CC(Br)=CS1 ZSCUXKJGNXUNNH-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 239000004214 Fast Green FCF Substances 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 208000002804 Osteochondritis Diseases 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004105 Penicillin G potassium Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JCABVIFDXFFRMT-DIPNUNPCSA-N [(2r)-1-[ethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCC=CCCCCCCCC JCABVIFDXFFRMT-DIPNUNPCSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- KYPIPCWVZKRJDD-UHFFFAOYSA-N benzotriazole-1-carboxylic acid Chemical compound C1=CC=C2N(C(=O)O)N=NC2=C1 KYPIPCWVZKRJDD-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 210000004439 collateral ligament Anatomy 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000019240 fast green FCF Nutrition 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- DODCBMODXGJOKD-RGMNGODLSA-N methyl (2s)-2-amino-4-methylpentanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC(C)C DODCBMODXGJOKD-RGMNGODLSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019368 penicillin G potassium Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Description
200520800 (1) 九、發明說明 【發明所屬之技術領域】 本發明係有關透明質酸與磷脂醯乙醇胺反應生成物之 透明質酸化合物,其水膠及關節治療用材料者。 【先前技術】 軟骨係活體內少數之無血管系組織之一者,不易於原 組織再行建造之。爲抑制基於外傷引起之軟骨缺損、折斷 性骨軟骨炎等局限之軟骨病變之變形性關節症的發症,被 嘗試各種治療方法。 採取由自體軟骨細胞或骨髓細胞之間葉系幹細胞,進 行分化之軟骨細胞於細胞、或培養基材(Scaffold )進行 培養後移植至軟骨缺損部之自體軟骨細胞移植者( Autologous Chondrocytes I mplantation ; ACI)被嘗試之 (N Engl J Me d. 331,889-95 ( 1994) ? J Bone Joint Surg Am. 76,5 79-92 ( 1 994 )及 Artificial Organs. 25,172-179 (200 1 ) ) 〇 又,活體外培養自體軟骨細胞時,被積極嘗試更接近 活體內環境之3元培養,做爲培養基材者可使用膠原、褐 藻酸、血纖維蛋白、等被認定於體內爲安全之材料。其中 針對膠原利用 Atelocollagen之方法被越智等進行開發, 開始進行臨床試驗(特開200 1 - 293 0 8 1號公報)。 惟,膠原雖爲活體吸收性,卻不易完全去除抗原性, 因此,是否將出現未知之病毒感染等危險性尙無法斷定等 -5- 200520800 (2) 課題存在。 對於此’透明質酸係形成關節軟骨之細胞外基質構成 成份者,與軟骨之親和性高。更且,透明質酸乃未含源於 動物之原料,以發酵法進行生成者,因此,不同於膠原, 其未知病毒感染等危險性低者。因而,最近於再生醫療中 ,被硏討利用透明質酸之膝軟骨損傷治療。 美國專利第5939323號明細書,J. Biomed. Mater. Res. 42,1 72-8 1 ( 1 998 ) ,J. Biomed. Mater. Res. 46? 3 3 7-46 ( 1 999 )及 J· Orthop· Res. 18,77 3 - 7 80 ( 2000 )中被揭 示苄酯化透明質酸者。又,特開平7— 97401號公報中, 被揭示雙環氧化物交聯透明質酸者。更於美國專利第 4 5 82 8 65號明細書及美國專利第460569 1號明細書中被揭 示二乙烯碾交聯透明質酸者,特開昭60 — 1 3 060 1號公報 中被揭示甲醛交聯透明質酸者,特開昭60 — 1 3 060 1號公 報中被揭示甲醛交聯透明質酸者。其他之醯肼交聯透明質 酸亦爲公知者。 【發明內容】 本發明目的係爲提供一種活體適用性佳,且安全之透 明質酸化合物者。 本發明目的係爲提供一種即使活體內載重部位仍可使 用之附與充份強度水膠之透明質酸化合物者。 本發明更有其他目的爲提供一種不溶於水性媒體之該 透明質酸化合物所成之成型體。 -6- 200520800 (3) 本發明更有其他目的爲提供一種由本發明該透明質酸 化合物所成之關節治療用材料者。 由以下說明’可更瞭解本發明其他目的及優點。 藉由本發明,其本發明該目的及優點係於第一藉由下 式(1)
(1) 其中 R爲下式 ch2ocor1 (1 ) r1co2ch
II ch2o -p-o —CH2CH2NH—— 0" (1) 一 所不之基^ — OH或—ONa者, R1爲碳數10〜28之烷基或脂烯基者,n爲50〜50, 〇〇〇 之數者,惟,R之1〜:100%爲該式(1 ) — a所示之基者, 所示之透明質酸化合物所達成者。 藉由本發明,其本發明該目的及優點係於第二藉由 本發明該透明質酸化合物所成之水膠所達成者。 藉由本發明,其本發明該目的及優點係於第三藉由 本發明該透明質酸化合物之成型體所達成者。 又,藉由本發明,其本發明該目的及優點係於第四藉 由本發明該透明質酸化合物所成之關節治療用材料所達成 -7 - 200520800 (4) 【實施方式】 〔發明實施之最佳形態〕 本發明透明質酸化合物係該式(1 )所示者。該式(1 )中,R代表式(Ο - a所示之磷脂醯乙醇胺基者、或、 一 OH或一 ONa者。惟,R之1〜! 00%務必爲磷脂醯乙醇胺 基者。磷脂醯乙醇胺基爲未達R之1 %時,將無法達成本 發明之目的。R爲碳數〜28者宜,較佳者爲碳數14〜20 之烷基或脂烯基者,η爲50〜50,000者宜,較佳者爲300〜 3 0,000,更佳者爲 1,000〜1 0,000。 做爲R碳數10〜28之烷基例者如:癸基、十一基、 月桂基、十三基、十四基、十五基、十六基、庚癸基、硬 脂醯、廿十基例者。又,做爲碳數10〜28之脂烯基例者如 :對應所示例之該烷基之具有1〜3個碳-碳不飽和鍵之脂 烯基例如:油烯基例者。 做爲該式(1 )所示化合物者以式(1 ) 一 a中之2個 基RkO—爲油醯基者宜。 該式(1 )所示之透明質酸化合物可藉由如:透明質 酸與磷脂醯乙醇胺相互反應後製造之。 做爲透明質酸者如:由動物組織所萃取者,或以發酵 法所製造者均可利用之。做爲發酵法所使用之菌株者可使 用具有鏈球菌屬之透明質酸產生能之微生物者、鏈球菌、 equi FM — 100 (特開昭 63 — 1 2 3 3 92號公報)、鏈球菌、 equi FM — 3 00 (特開平2 — 23 46 8 9號公報)爲公知者。利 200520800 (5) 用此等變異株後,進行培養,精製者亦可使用之。又,透 明質酸之分子量以約lxio5〜lxio7者宜。另外,其中透 明質酸亦包含其鹼金屬鹽,如:鈉、鉀、鋰之鹽者。 更有做爲磷脂醯乙醇胺者可使用由動物組織所萃取者 、或合成所製造之任意者。磷脂醯乙醇胺例者如:二月桂 醯磷脂醯乙醇胺、二肉豆蔻醯磷脂醯乙醇胺、二棕櫚醯磷 脂醯乙醇胺、二硬脂醯磷脂醯乙醇胺、二花生醯磷脂醯乙 醇胺、二山榆基磷脂醯乙醇胺、二巴西棕櫚醯磷脂醯乙醇 胺、二蠟油磷脂醯乙醇胺、二褐媒磷脂醯乙醇胺、二月桂 油醯磷脂醯乙醇胺、二肉豆蔻油醯磷脂醯乙醇胺、二棕櫚 醯磷脂醯乙醇胺、二油醯磷脂醯乙醇胺、二神經醯磷脂醯 乙醇胺、磷脂醯乙醇胺衍生物(Diximenoyl Pho sphatidyl ethanol ami ne )、二亞麻醯磷脂醯乙醇胺、磷 脂醯乙醇胺衍生物(Dihiragonoyl
Phosphatidylethanolamine)、二花生醯磷脂醯乙醇胺、二 廿六碳六醯磷脂醯乙醇胺之例者。其中又以二油醯磷脂醯 乙醇胺其溶解性面較爲理想者。 磷脂醯乙醇胺於活體中爲安全物質者,本發明做爲透 明質酸化合物之透明質酸利用氫結合或疏水性相互作用之 物理交聯等促進交聯。因此,本發明之透明質酸化合物可 藉由此等交聯後形成後述之水膠、不溶性成型體者。 磷脂醯乙醇胺之使用量針對每1 0 0當量之透明質酸之 羧基爲1〜100當量者宜。若少於1當量則所生成之透明質 酸化合物未能形成水膠。反之,多於5 0當量則所生成之 -9 - 200520800 (6) 透明質酸化合物之疏水性變高,產生不溶物’而不易形成 水膠,特別是,5 1當量以上之使用量時’則對水性媒體 出現極不溶性者。其中水性媒體係指含有水、生理食鹽水 、緩衝液及醇等有機溶媒之水溶液之意者,又,不溶性係 指某一定期間透明質酸化合物滯留於活體內,隨後,漸漸 分解,最後被吸收於活體內之意者。 相較於注入化合物於動物如:人類膝關節類之載重活 體膝關節部位時不易於200Pa以下維持形狀者,而,本發 明由透明質酸化合物所成之水膠則具有2 0 0 P a以上之高彈 性率,因此適用做爲膝軟骨損傷治療用之材料者。 本發明透明質酸化合物於水性媒體中,出現極不溶性 時,此可呈成型體如··海綿類多孔體、不織布、薄膜等形 狀進行成型之。又,本發明透明質酸化合物即使於水性媒 體呈不溶性仍可於埋入成型體於體內時2〜3週後,藉由體 液進行膨潤後轉換呈凝膠者。 做爲製造成型體之方法者如:凍結乾燥法、乾式製膜 、濕式製膜、凝固紡紗、紡黏法、熔融吹燃法、快速紡紗 法等例。 此等成型體可適用於具一定形狀做爲成型體使用後務 必修復軟骨時之用途者’特別期待高度滯留性之用途,如 •關節治療、術後組織之癒合預防劑或皮膚之保濕劑等者 〇 本發明透明質酸化合物可適用於具有如上述之軟骨修 復能力之關節治療用材料者。 -10- 200520800 σ) 〔實施例〕 藉由以下之實施例進行本發明更詳細具體之說明。惟 ,本發明未受限於此等實施例者。 以下實施例1〜4所使用之透明質酸鈉係其源於鏈球菌 屬之平均分子量爲1,〇〇〇,〇〇〇之透明質酸鈉者,此相當於 η = 3,5 00者。針對其他試藥四氫呋喃,0.1Μ HC1、0.1Μ NaOH、1—乙基一3— 〔3—(二甲基胺)丙基〕一羧二一 亞胺(EDC ) 、:I 一羥基苯並三唑(HOBt ) 、:L —白胺酸 甲基酯氫氯化物爲和光純藥工業(股份)、L 一 α -二油 醯磷脂醯乙醇胺(COATSOME ME— 8181)爲日本油脂( 股份),3% At elo collagen爲高硏(股份)者使用之。 〔實施例1〕 將 110mg( 0.00003 3 mol)(針對每1〇〇當量透明質 酸之羧基爲10當量)之L一 α —二油醯磷脂醯乙醇胺溶 解於 2 0 0 m£之四氫呋喃/水=1 / 1 ( W ν )。此溶液中加入 500mg之透明質酸鈉,再添加0.1 MHC1/0.1M NaOH,調 整 pH 爲 6·8。將 30mg( 0.000033mol)之 1—乙基一3 — 〔3—(二甲胺)丙基〕一羧二亞胺(EDC ) 、25mg ( 0.000033 niol)之1—經基苯並三卩坐(HOBt)溶於10”i之 四氫呋喃/水=1/1之水溶液後,加入反應系,進行整夜攪 拌。攪拌後,進行透析精製,凍結乾燥後,取得目的物。 藉由1HNMR (日本電子JNM — α400)進行確定後,確定 -11 - 200520800 (8) 目的物之生成。 將3 0mg此凍結乾燥品溶於970mg離子交換水後,調 整濃度3 wt%之水膠。爲測定此水膠之複彈性率及滑動降 伏應力,利用 Rheometer RFIII、SRV (ΤΑ Instrument) 於3 7°C下進行測定之。其結果示於表1。其中複彈性率係 指彈性體之應力與變形之比定數者,滑動降伏應力係指懸 吊滑動應力時,顯示維持凝膠結構之最大應力。 〔實施例2〕 除使用440mg( 0.000 1 2mol)(針對每100當量透明 質酸之羧基爲4〇當量)之-二油醯碟脂醯乙醇胺 ,120mg( 0.000132mol)之 1—乙基一3— 〔3— 一 甲胺) 丙基〕一羧二亞胺(EDC ) 、100mg ( 0·000 1 3 2ιηο1 )之 1 一羧基苯並三唑(Η Ο B t )之外,與實施例1同法進行之 。結果示於表1。 〔比較例1〕 於5 0 m g之透明質酸鈉中加入5 離子交換水進行攪 拌後,取得水膠。針對物性評定’與實施例1同法進行之 。結果示於表1。 〔比較例2〕 參考用再追加試驗美國專利第4,9 3 7,2 7 0號明細書。 其詳細內容如下。 -12- 200520800 Ο) 將40 0mg之透明質酸鈉溶於40 2水中,藉由0.1M HC1進行調整pH爲4.75。 添力口 153mg(0.80mmol)之 1—乙基一3— 〔3— ( __. 甲胺)丙基〕—羧二亞胺(EDC ) 、1 82mg ( 1 .Ommol )之 L -白胺酸甲酯氫氯化物,進行攪拌5小時。攪拌後,進 行透析精製,凍結乾燥後取得目的物。與實施例1同法進 行物性評定。其結果示於表1。 〔比較例3〕 除使用 Atelocollagen之外,與實施例1同條件下測 定Atelo collagen。其結果示於表1。 表1 X 材料 複彈性率 (Pa) 滑動降伏應力 (Pa) 實施例1 透明質酸-L- α -油烯磷 脂醯乙醇胺 (1 0 m ο 1 %) 42 1 1,083 實施例2 透明質酸-L-α -油烯磷 脂醯乙醇胺 (4 0 m ο 1 %) 902 1,734 比較例1 透明質酸鈉 5 18 比較例2 交聯透明質酸 5 13 5 15 比較例3 Atelocollagen 293 91 9 -13- 200520800 (10) 由表1證明,透明質酸一 L 一 α -二油醯磷脂醯乙醇 胺相較於透明質酸鈉,Atelo collagen後,其複彈性率、 降伏滑動應力均較理想者。又,相較於交聯透明質酸’亦 顯示同等或其以上之機械特性。 〔實施例3〕
將1 0 0 m g透明質酸鈉溶於4 0 之四氫呋喃1水=1 / 1 (Wv )水溶液。此水溶液中加入 1 5 4mg ( 0.0002 1 mol )
(針對每100當量透明質酸之羧基爲70當量)之L—α 一二油醯磷脂醯乙醇胺,添加0.1M HC1/0.1M NaOH進行 調整 pH 爲 6.8。使 42mg (0.000231 mol)之 1 一乙基—3 一 〔3—(二甲胺)丙基〕一羧二亞胺(EDC) 、35mg( 0·000231πιο1)之1—羥基苯並三唑(HOBt)溶於10J之 四氫呋喃/水=1 / 1 ( V/V )後,加入反應系。此時,添加 0 · 1 Μ N a Ο Η使反應系維持於p Η 6 · 8。隨後,進行整夜攪 拌,攪拌之後,進行透析3天後,凍結乾燥後取得目的物 (海綿)。藉由1hNMR (日本電子jniv[- α400)進行確 定,確定目的物之生成。 藉由以下方法進行溶解性試驗。將2〇mg取得之目的 物浸漬於5 4之磷酸緩衝生理食鹽水後,針對室溫靜置狀 態下之溶解性,進行試驗4週,以目測進行確定。溶解性 試驗之結果示於表2。 -14- 200520800 (11) 〔實施例4〕 除取 223mg( 0.0003mol)(針對每1〇〇當量透明質 酸之羧基爲100當量)之L—α -二油醯磷脂醯乙醇胺、 60mg (0.00033 mol)之 1 一乙基一3— 〔3—(二甲胺)丙 基〕—羧二亞胺(EDC) ,50mg( 0.00033m〇l)之 1—羥 基苯並三唑(HOBt )之外,與實施例1同法取得目的物 (海綿)。溶解性試驗之結果如表2所示。 〔比較例4〕 將2 0 m g之透明質酸鈉浸漬於5 之磷酸緩衝生理食 鹽水後,針對室溫靜置狀態下之溶解性進行試驗4週,以 目測進行確定。結果示於表2。 表2 \ L-α -二油醯憐脂醯乙 醇胺含有量(當量)U 1曰 1週間 2週間 4週間 實施例3 70 〇 〇 〇 〇 實施例4 100 〇 〇 〇 〇 比較例4 0 X X X X ----1 〇:未溶解,△:部份溶解,X :完全溶解 1 )針對每1〇〇當量透明質酸之羧基的量 由表2證明透明質酸- L 一 α -二油醯磷脂醯乙醇胺 (含量:70,1 〇〇當量)相較於透明質酸鈉,其對於水性 -15- 200520800 (12) 液體較可促使透明質酸之不溶化者。 使用以下實施例5之消毒用乙醇,1 〇 %中性緩衝甲醛 水溶液’藏紅0溶液爲和光純藥工業(股份)之市販品 ’ Fast Green FCF爲polyscience (股份)之巾販品、乙烯 二胺一N,N,N,,N,—四醋酸、四鈉鹽、四水解物(以 下EDTA )爲同仁化學硏究所(股份)之市販品、戊巴比 妥(以下Nembutal )爲大日本製藥(股份)之市販品、 1%利多卡因爲 Astrazrurka (股份)之市販品、結晶青黴 素G鉀(以下青黴素)爲萬有製藥(股份)之市販品、 優碘爲吉田製藥(股份)之市販品者。又,實施例5所使 用之紐西蘭白色家兔(以下NZW兔)爲雄性者,由曰本 S LC (股份)購入後,以計表進行一般飼養至體重爲 3.0〜3.5kg爲止。手術後之週齡爲24〜28週齡。 〔實施例5〕 藉由以下方法進行實施例1所調整之濃度3 wt°/〇之透 明質酸水膠之生物學評定。於一般飼養之N Z W兔之耳介 靜脈投入戊巴比妥後,全身麻醉下進行以下手術。進行兩 側後肢膝關節週邊部份之剃毛後,進行乙醇消毒,將利多 卡因分數次局部性進行肌肉內投入。切開膝關節內側,使 膝蓋骨脫臼後露出大腿骨膝蓋溝。由內側側副韌帶5mm 之上部滑車溝部份以手術用鈷頭製作內徑5mm、深度 5mm之圓筒形缺損部’使膝關節軟骨全層缺損之。將上 記取得之水膠埋入其缺損部後’使膝蓋骨歸回原位進行手 -16- 200520800 (13) 術用縫合肌肉。爲預防感染,於患部滴入青黴素,縫合皮 膚。最後以優碘進行消毒,回復計表進行一般飼養。術後 第8週,進行屠殺摘出缺損部份,於1 0%中性緩衝甲醛水 溶液中進行浸漬,固定後,供於組織學評定。將固定之組 織進行脫脂,EDTA脫灰後,包埋於石鱲,使缺損部中心 部附近進行薄切呈矢狀面,製成標本。於所製成之標本上 進行藏紅0之染色,針對以下項目藉由分級化進行組織 學之評定。 組織學評定所使用之分級度數係藉由 Wakitani S et al·,J Bone J o i n t S u i* g A m · 7 6,5 7 9 - 9 2 ( 1 9 9 4 )之變法之 Makino T et al.? kobe J Med Sci. 48 : 97- 1 04 ( 2002 )進 行實施。表3顯示組織學評定時所利用之項目及得點。 總計爲14點,依項目以3〜5階段進行評定。組織修 復度愈高,亦即,愈接近正常組織之修復,接近1 4點者 。亦即,項目爲被修復組織之形態(〇點〜4點)、基質染 色性(〇點〜3點)、表面狀態(0點〜3點)、軟骨組織之 厚度(〇點〜2點)、非缺損部相互結合度(〇〜2點)者, 本方法中愈接近正常組織,其得點愈高者。 圖1顯示術後第8週摘出缺損部位所進行組織學評定 之結果者。術後第8週被修復之軟骨組織幾乎呈玻璃軟骨 樣,呈產生良好基質樣者。又,與正常部之結合亦良好者 ,出現組織連續性。 〔比較例5〕 -17- 200520800 (14) 與實施例5同法製作於大腿骨滑車溝之缺損部份後, 埋入Atelocollagen (註冊商標)(I型,(股份)高硏) ,進行整復後,於術後第8週摘出缺損部份進行組織學評 定之結果示於圖1。 相較於實施例5,其基質之染色雖與其他條件未有出 入’惟,表面不平滑、軟骨下骨完全無法再重建。
-18- 200520800 (15) 表3 針對軟骨欠損之組織學評定 A.細胞之形態 4以玻璃軟骨構成、正常 3多半以玻璃軟骨修復 1幾乎以非軟骨組織修復 0完全無軟骨組織 B.藉由藏紅〇之基質染色性 3與(正常部位比較)同等之 染色性 2稍降低 1極低 〇無染色性 C.表面形態1 3 平滑(>3/4 ) 2中程度(1/2〜3/4 ) 1凹凸不平(1/4〜1/2 ) 0凹凸嚴重(<1/4) D .軟骨組織之厚度〃 2 >2/3 11/3—2/3 0 <1/3 E.針對接近正常部分之修 復部分的一例 2兩端均呈一體化( 1單端一體化 〇 兩_均未呈~體化^ 合計A — E _ [ 0 — 14
-19- 1 針對全體缺損部分之平滑部分比例 * 1修復部與正常部位比較後之平均厚度 200520800 (16) 由以上結果’證明實施例5與比較例5其基質染色性 所修復之軟骨組織厚度爲相同者,惟,實施例5之表面狀 < 態與正常組織之組織學性連續性之修復接近正常組織、整 體顯示良好修復能者。 由此證明,本發明之透明質酸與磷脂醯乙醇胺二油醯 · 所成之透明質酸化合物相較於比較例(Atelocollagen )其 , 做爲軟骨治療用材料爲較理想者。 【圖式簡單說明】 圖1係代表實施例5及比較例5中,對比術後8週兔 子膝關節之組織學評定者。 攀 •20·
Claims (1)
- 200520800 (1) 十、申請專利範圍 1. 一種透明質酸化合物,其特徵係下式(1 )所示者其中,R表示下述式(1) 一 ch2ocor1 r1co2〒h ? CH20 - p-o —ch2CH2NH-〇- (1)- 所示之基,—OH或—ONa者,R】代表碳數10〜2 8之 烷基或脂烯基者,η爲50〜50,000之數者,惟,r之 1〜100 %爲上式(1) — a所代表之基者。 2 ·如申請專利範圍第1項之透明質酸化合物,其中 該η爲300〜30,000者。 3 ·如申請專利範圍第1項之透明質酸化合物,其中 該式(1) 一 a中2個基R^CO-均爲油醯基者。 4 · 一種水膠’其特徵係由如申請專利範圍第1項至 第3項中任一項之透明質酸化合物所成者。 5 · —種成型體,其特徵係如申請專利範圍第1項至 第3項中任一項之透明質酸化合物者。 6· 一種關節治療用材料,其特徵係由如申請專利範 -21 - 200520800 (2) 圍第1項至第3項中任一項之透明質酸化合物所成者。 7 ·如申請專利範圍第6項之關節治療用材料,其中 該材料爲具有軟骨修復能力者。 8 · —種使用,其特徵係做爲如申請專利範_ _ _弟1項 之透明質酸化合物之關節治療用材料者。 〜 -22-
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003368540 | 2003-10-29 | ||
JP2004205682 | 2004-07-13 | ||
JP2004274775 | 2004-09-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200520800A true TW200520800A (en) | 2005-07-01 |
TWI344852B TWI344852B (zh) | 2011-07-11 |
Family
ID=34527599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093132785A TW200520800A (en) | 2003-10-29 | 2004-10-28 | Hyaluronic acid compound, hydrogel thereof and material for treating joint |
Country Status (6)
Country | Link |
---|---|
US (1) | US8137685B2 (zh) |
EP (1) | EP1681306B1 (zh) |
JP (1) | JP4511470B2 (zh) |
ES (1) | ES2406555T3 (zh) |
TW (1) | TW200520800A (zh) |
WO (1) | WO2005040224A1 (zh) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2861734B1 (fr) | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
WO2010132402A1 (en) * | 2009-05-11 | 2010-11-18 | Morria Biopharmaceuticals, Inc | Lipid-polymer conjugates, their preparation and uses thereof |
CA2687990A1 (en) * | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Cross-linked collagen and uses thereof |
US8318695B2 (en) * | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
EP3498299A1 (en) | 2007-11-16 | 2019-06-19 | Aclaris Therapeutics, Inc. | Compositions and methods for treating purpura |
US8394784B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
US8394782B2 (en) * | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US8357795B2 (en) | 2008-08-04 | 2013-01-22 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
JP2010035744A (ja) * | 2008-08-04 | 2010-02-18 | Teijin Ltd | 癒着防止材 |
CA2731791A1 (en) * | 2008-08-05 | 2010-02-11 | Teijin Limited | Hydrogel |
US8462765B2 (en) * | 2008-08-20 | 2013-06-11 | Qualcomm Incorporated | Method and apparatus to perform ranging operations for wireless stations |
EP3184552B1 (en) | 2008-09-02 | 2020-08-12 | Tautona Group LP | Threads of hyaluronic acid, methods of making thereof and uses thereof |
MX2011010807A (es) * | 2009-04-17 | 2011-11-01 | Teijin Ltd | Derivado de polisacarido e hidrogel del mismo. |
US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US20110171311A1 (en) * | 2010-01-13 | 2011-07-14 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
CA2792729C (en) | 2010-03-12 | 2016-06-28 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
CA2794254C (en) | 2010-03-22 | 2018-09-04 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
CA2703532C (en) * | 2010-05-10 | 2018-05-01 | Eva Turley | Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
CN103987402B (zh) | 2011-12-09 | 2019-06-18 | 麦特保利药业有限公司 | 生长激素片段的用途 |
WO2016051219A1 (en) | 2014-09-30 | 2016-04-07 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
JP6285882B2 (ja) * | 2015-02-04 | 2018-02-28 | 帝人株式会社 | ヒアルロン酸誘導体および医療用製剤 |
WO2016128783A1 (en) | 2015-02-09 | 2016-08-18 | Allergan Industrie Sas | Compositions and methods for improving skin appearance |
KR20220119648A (ko) * | 2019-12-20 | 2022-08-30 | 메사추세츠 인스티튜트 오브 테크놀로지 | 히알루론산 유도체 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60130601A (ja) | 1983-12-15 | 1985-07-12 | バイオマトリツクス,インコ−ポレイテツド | ヒアルロン酸水不溶性組成物の製法 |
US4605691A (en) | 1984-12-06 | 1986-08-12 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4582865A (en) | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
JPS63123392A (ja) | 1986-11-14 | 1988-05-27 | Denki Kagaku Kogyo Kk | ヒアルロン酸の製造方法 |
US4937270A (en) | 1987-09-18 | 1990-06-26 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
IL84252A (en) * | 1987-10-23 | 1994-02-27 | Yissum Res Dev Co | Phospholipase inhibiting compositions |
JPH02234689A (ja) | 1989-03-09 | 1990-09-17 | Denki Kagaku Kogyo Kk | ヒアルロン酸の製造方法 |
JP2997018B2 (ja) | 1990-07-24 | 2000-01-11 | 生化学工業株式会社 | 燐脂質又は脂質結合グリコサミノグリカン |
US5733892A (en) * | 1990-07-24 | 1998-03-31 | Seikagaku Corporation | Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same |
DE69124590T2 (de) * | 1990-07-24 | 1997-06-12 | Seikagaku Kogyo K K Seikagaku | Glykosaminoglykan gemischt mit phospholipid oder lipid, seine herstellung und krebszellenmetastaseninhibitor |
US5603872A (en) | 1991-02-14 | 1997-02-18 | Baxter International Inc. | Method of binding recognizing substances to liposomes |
JP3199405B2 (ja) * | 1991-08-30 | 2001-08-20 | 生化学工業株式会社 | 肝細胞球状集塊化剤及び球状集塊化肝細胞の製造方法 |
JP3714683B2 (ja) * | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | 抗リウマチ剤 |
JP3107488B2 (ja) | 1993-09-29 | 2000-11-06 | 株式会社資生堂 | 架橋ヒアルロン酸を用いた徐放性製剤及び塞栓剤 |
US5827937A (en) | 1995-07-17 | 1998-10-27 | Q Med Ab | Polysaccharide gel composition |
JPH0959303A (ja) | 1995-08-22 | 1997-03-04 | Shiseido Co Ltd | 生体適合性ヒアルロン酸ゲル及びその用途 |
WO1997045532A1 (en) | 1996-05-28 | 1997-12-04 | Brown University Research Foundation | Hyaluronan based biodegradable scaffolds for tissue repair |
IT1303735B1 (it) | 1998-11-11 | 2001-02-23 | Falorni Italia Farmaceutici S | Acidi ialuronici reticolati e loro usi medici. |
JP3032824B1 (ja) * | 1999-01-28 | 2000-04-17 | 東京医科歯科大学長 | 骨誘導促進剤 |
JP2001293081A (ja) | 2000-02-07 | 2001-10-23 | Mitsuo Ochi | 軟骨移植用材料及びその製造方法 |
US20020012998A1 (en) * | 2000-03-29 | 2002-01-31 | Igor Gonda | Cationic liposomes |
-
2004
- 2004-10-27 ES ES04793318T patent/ES2406555T3/es active Active
- 2004-10-27 JP JP2005515059A patent/JP4511470B2/ja not_active Expired - Fee Related
- 2004-10-27 WO PCT/JP2004/016285 patent/WO2005040224A1/ja active Application Filing
- 2004-10-27 US US10/577,154 patent/US8137685B2/en not_active Expired - Fee Related
- 2004-10-27 EP EP04793318A patent/EP1681306B1/en not_active Not-in-force
- 2004-10-28 TW TW093132785A patent/TW200520800A/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1681306A1 (en) | 2006-07-19 |
WO2005040224A1 (ja) | 2005-05-06 |
EP1681306B1 (en) | 2013-02-20 |
US8137685B2 (en) | 2012-03-20 |
US20080193538A1 (en) | 2008-08-14 |
EP1681306A4 (en) | 2007-03-28 |
JP4511470B2 (ja) | 2010-07-28 |
TWI344852B (zh) | 2011-07-11 |
ES2406555T3 (es) | 2013-06-07 |
JPWO2005040224A1 (ja) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200520800A (en) | Hyaluronic acid compound, hydrogel thereof and material for treating joint | |
Li et al. | Recruitment of multiple cell lines by collagen-synthetic copolymer matrices in corneal regeneration | |
Lai et al. | Characterization of cross-linked porous gelatin carriers and their interaction with corneal endothelium: biopolymer concentration effect | |
US20170182214A1 (en) | Compositions and methods for scaffold formation | |
JP2018177818A (ja) | ヒアルロン酸/コラーゲン系真皮充填剤組成物およびそれを作製するための方法 | |
EP2999494B1 (en) | Anti-thrombogenic grafts | |
CN1340080A (zh) | 透明质酸凝胶组合物、其制造方法及含该组合物的医用材料 | |
EP3016693A1 (en) | Dissolvable hydrogel compositions for wound management and methods of use | |
JP2008505716A (ja) | ヒドロキシフェニル架橋高分子ネットワーク及びその用途 | |
KR20080065973A (ko) | 상호침투성 망상구조, 및 관련 방법 및 조성물 | |
CA3115998A1 (en) | Bioadhesive for soft tissue repair | |
US20200179419A1 (en) | Method for the manufacture and use of a bionic hydrogel composition for medical applications | |
JP6933393B2 (ja) | 皮膚異常の処置のための治療用化粧品 | |
US10111982B2 (en) | Pepsinized collagen implants and biomedical uses thereof | |
US20210244659A1 (en) | Compositions and methods for in situ-forming tissue constructs | |
Kim et al. | Preparation and properties of collagen/modified hyaluronic acid hydrogel for biomedical application | |
JP6933394B2 (ja) | 組織再生誘導のためのバイオマテリアルデバイスおよび局所用組成物 | |
KR20160135596A (ko) | 가교화된 pva-ecm 복합체를 제조하는 방법 및 그에 의하여 제조된 pva-ecm 복합체 | |
JP2019513868A (ja) | ヒアルロン酸コンジュゲートおよびその使用 | |
EP1543846B1 (fr) | Hydrogel biorésorbable réticulé à base d'albumine | |
US20220218465A1 (en) | Modified extracellular matrix-based hydrogel, manufacturing method of the same and use of the same | |
US20240058508A1 (en) | Composition for preparing organic-inorganic complex hydrogel and kit for preparing organic-inorganic complex hydrogel comprising same | |
Lan et al. | Swim bladder-derived biomaterials: structures, compositions, properties, modifications, and biomedical applications | |
US20210220515A1 (en) | Viscoelastic agent material | |
Sani | Hydrogel-Based Bioadhesives for Tissue Engineering and Surgical Applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |